AGM/EGMApr 29, 2026, 04:39 PM
LCTX Annual Meeting June 10, 2026: Elect 7 Directors, Ratify Auditor
AI Summary
Lineage Cell Therapeutics, Inc. announced its 2026 Annual Meeting of Shareholders to be held on June 10, 2026. Shareholders will vote on the election of seven directors, the ratification of Baker Tilly US, LLP as the independent registered public accounting firm for fiscal year 2026, and an advisory approval of named executive officer compensation. The record date for voting was April 20, 2026, with 249,298,295 common shares outstanding. The filing also detailed non-employee director compensation for 2025, including cash fees and annual stock option grants of 75,000 shares.
Key Highlights
- Annual Meeting of Shareholders scheduled for June 10, 2026, at 8:00 a.m. Pacific Time.
- Shareholders to elect seven directors to the Board of Directors.
- Proposal to ratify Baker Tilly US, LLP as independent auditor for 2026.
- Advisory vote on compensation paid to named executive officers.
- Record date for voting is April 20, 2026, with 249,298,295 common shares outstanding.
- Non-employee directors received annual stock options for 75,000 common shares in 2025.
- Board Chair Michael H. Mulroy's total 2025 compensation was $160,990.
- Deborah Andrews' total 2025 compensation was $123,490.
Price Impact
More from LCTX